With IL-12 prospect nearing clinic, Ankyra inks NCI pact to support cancer pipeline progressnews2022-04-18T12:47:53+00:00April 18th, 2022|FierceBiotech|
Emergex’s synthetic T-cell adaptive vaccines close in on data in dengue, COVID-19news2022-04-18T12:13:16+00:00April 18th, 2022|FierceBiotech|
U2 disbands: In a crushing step back, TG retracts FDA request for combo therapy due to death risknews2022-04-15T14:38:21+00:00April 15th, 2022|FierceBiotech|
UPDATE: TG disbands cancer program after pulling FDA request for U2 combo therapynews2022-04-15T14:38:21+00:00April 15th, 2022|FierceBiotech|
Dutch courage: Netherlands makes $350M bet on patient-centered preclinical cancer drug developmentnews2022-04-15T07:27:15+00:00April 15th, 2022|FierceBiotech|
Game over: Bristol Myers, Nektar end $3.6B immuno-oncology program after 2 more late-stage flopsnews2022-04-15T06:35:08+00:00April 15th, 2022|FierceBiotech|
Chutes & Ladders—Former CVS exec Denton, responsible for Aetna merger, tapped by Pfizer for CFO rolenews2022-04-15T03:05:45+00:00April 15th, 2022|FierceBiotech|
AstraZeneca’s Alexion, Arvinas nab space at future 10-story biotech tower in New Havennews2022-04-14T21:29:01+00:00April 14th, 2022|FierceBiotech|
FDA urges creation of racial, ethnic recruitment plans for clinical trialsnews2022-04-14T17:58:40+00:00April 14th, 2022|FierceBiotech|
Evelo hits the brakes on atopic dermatitis drug development after phase 1 failurenews2022-04-14T15:52:13+00:00April 14th, 2022|FierceBiotech|
